Updates from the ASCO 2022 Conference
ASCO (American Society of Clinical Oncology) is an important conference in the oncology community where new scientific research updates are shared. The Life Raft Group is excited to present Dr. Andrew Wagner and Dr. Herbert Loong, who will summarize abstracts and presentations that were presented during this conference that are relevant to the GIST patient community.
About our Presenters:
Andrew J. Wagner, MD
Dana-Farber Cancer Institute
Dr. Wagner is the Deputy Chief Medical Officer at Dana-Farber Cancer Institute and the Medical Director of Adult Ambulatory Oncology. As a medical oncologist and translational researcher in the Center for Sarcoma and Bone Oncology and Associate Professor of Medicine at Harvard Medical School, Dr. Wagner focuses on the treatment of patients with GIST and sarcoma, and conducts laboratory research and clinical studies to identify new targets and treatments for these diseases. He received a PhD in Biochemistry and Molecular and an MD from the University of Chicago Pritzker School of Medicine. Dr. Wagner completed his Internship and Residency in Internal Medicine at Brigham and Women’s Hospital in Boston, where he later served as Chief Medical Resident. He completed a fellowship in Hematology and Medical Oncology at Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Massachusetts General Hospital, and then joined the Oncology Staff at Dana-Farber where he is currently a Senior Physician in the Department of Medical Oncology.
Herbert H. Loong, MBBS, PDipMDPath, MRCP(UK), FRCP Edin, FHKCP, FHKAM(Medicine)
The Chinese University of Hong Kong
Dr. Loong holds conjoint appointments of Clinical Associate Professor in the Department of Clinical Oncology and Deputy Medical Director of the Phase 1 Clinical Trials Centre of The Chinese University of Hong Kong. He is also the current and founding convenor of the Prince of Wales Hospital Adult Sarcoma Multidisciplinary Team.
He obtained his medical degree with a Distinction in Surgery from The University of Hong Kong in 2003. He has completed a Fellowship in Drug Development at Princess Margaret Cancer Centre in Toronto, Canada with a special focus on Experimental Therapeutics. His clinical and research interests also include Sarcoma Medical Oncology, Thoracic Oncology and Health Economics.
Dr. Loong is a recipient of the European Cancer Congress Fellowship Grant (2013), the American Society of Clinical Oncology (ASCO) Annual Meeting Merit Award (2014), the Hong Kong College of Physicians Young Investigators’ Award (2014). Nominated by patients and their caregivers, Dr. Loong led the Lung Cancer Team at CUHK to be bestowed the IASLC Foundation Cancer Care Team Award in recognition for providing the best thoracic oncology care in “Asia & Rest of the World” in 2018.
Dr. Loong has served/continues to serve in various capacities in various professional international oncology bodies, including the International Affairs Committee and the Asia-Pacific Regional Council of ASCO, the Membership, Education and Communications Committees of the IASLC. He has been elected as a Board Member of the Connective Tissue Oncology Society (CTOS) for 2022-2024. He is also a founding executive committee member of the newly formed Asia Pacific Oncology Drug Development Network (APODDC). He is also a Board Member in the specialty of Medical Oncology in the Hong Kong College of Physicians. In his appointment as a Registration Committee member of Pharmacy and Poisons Board of Hong Kong, he helps oversee the registration of medicinal products and clinical trials in the territory.